Aya Mohamed | MSc, MD π (@Dr_Oncologista) ranks #8 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 30 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: NATALEE, DESTINYBreast-09, DeLLphi-304.
At a Glance
- 48 posts naming a trial in 2026
- 36 trials discussed by name
- Breast Cancer: US #8, Global #13 Β· 30 physicians engaged
- Leading physician voice: #2 of 13 physicians on DESTINYBreast-09; #2 of 3 physicians on PANKUBREAST02
This Month
What Aya Mohamed | MSc, MD π has posted in the last 30 days. Updated November 10, 2026.
DESTINY-Breast09: #ESMO26 T-DXd + pertuzumab showed encouraging systemic and intracranial activity in 1L HER2+ mBC with baseline brain metastases, with CNS-PFS HR 0.26 vs THP. @OncoAlert #BreastCancer #bcsm #ESMOAmbassadors #ESMOcommunity @myESMO https://t.co/FO2eHAPYUZ
ASTRIDE:π« Serplulimab + chemotherapy showed a numerical OS advantage over atezolizumab + chemotherapy in 1L ES-SCLC (12.4 vs 10.2 months; HR 0.82). @OncoAlert #ESMO26 #LungCancer #ESMOAmbassadors #Lcsm #ESMOcommunity @myESMO https://t.co/bPg1KaXs5j
DeLLphi-304: π« Tarlatamab sustained its OS benefit at 23-month follow-up, improving median OS to 13.6 vs 8.4 months (HR 0.62) @OncoAlert #ESMO26 @ESMO_Open #ESMOAmbassadors #LungCancer #ESMOcommunity @myESMO https://t.co/tqxtg7Mg1p
OptiTROP-Breast01: Sac-TMT improved median OS in pretreated mTNBC (14.7 vs 9.9 months; HR 0.60), reinforcing the role of ADCs in later-line treatment. @OncoAlert #ESMO26 #ESMOAmbassadors #ESMOcommunity @myESMO #BreastCancer #bcsm https://t.co/KExulTOhAR
SWITCH highlights the limited activity of sequential ADCs after progression in metastatic HER2-negative breast cancer: ORR 0β8.3%, median PFS 1.4β3.0 months @OncoAlert #ESMO26 #BreastCancer #bcsm #ESMOAmbassadors #ESMOcommunity @myESMO https://t.co/RaLX9nNSkM
OptiTROP-Lung06:π« Sac-TMT + pembrolizumab improved median PFS in PD-L1βnegative advanced nonsquamous NSCLC (15.0 vs 5.7 months; HR 0.49), with fewer grade 3 or higher adverse events. OS remains immature; follow-up is key. @OncoAlert #ESMO26 #LungCancer #ESMOcommunity @myESMO https://t.co/nIAg7uYbdI
Next meeting to watch: SABCS 2026 Β· San Antonio Β· Dec 8β11, 2026
Who Amplifies Aya Mohamed | MSc, MD π
Physicians who reposted Aya Mohamed | MSc, MD πβs trial posts most often in 2026.
- SG
Saffet Guleryuz15 reposts - CM
Christine Michel12 reposts - JF
Jose Fernando Moura, PhD5 reposts - AS
Abi Siva MD5 reposts - YK
Yoichi Koyama, MD, PhD4 reposts - BR
Brandon Rose, MD, MPH3 reposts - GL
gilberto lopes3 reposts - NR
Nirmal Raut3 reposts - ST
Sara Tolaney2 reposts - ?
ππ‘ππ§ππ₯ππ« πππ«π€ ππ π
πππ2 reposts
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #8 | #13 | 30 | 70 | Full ranking |
Trials Aya Mohamed | MSc, MD π Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| NATALEE | 4 | #18 of 46 | Oct 26, 2026 |
| DESTINYBreast-09 | 3 | #2 of 13 | Oct 26, 2026 |
| DeLLphi-304 | 2 | #8 of 23 | Oct 26, 2026 |
| OptiTROP-Lung06 | 2 | #7 of 29 | Oct 26, 2026 |
| TROPION-Breast02 | 2 | #9 of 26 | Oct 24, 2026 |
| postMONARCH | 2 | #5 of 18 | Oct 24, 2026 |
| DESTINYBreast-05 | 2 | #8 of 11 | Oct 23, 2026 |
| HER2CLIMB-05 | 2 | #6 of 19 | Oct 7, 2026 |
| EVERA | 2 | #11 of 30 | Oct 1, 2026 |
| SERENA-6 | 2 | #17 of 39 | Jul 14, 2026 |
| LIBRETTO-432 | 2 | #16 of 53 | Jun 1, 2026 |
| ASTRIDE | 1 | #4 of 7 | Oct 26, 2026 |
| OptiTROP-Breast01 | 1 | #4 of 12 | Oct 26, 2026 |
| SWITCH | 1 | #15 of 23 | Oct 26, 2026 |
| BRIDGET | 1 | #13 of 17 | Oct 26, 2026 |
| LITESPARK-012 | 1 | #9 of 21 | Oct 25, 2026 |
| VIKTORIA-1 | 1 | #12 of 23 | Oct 24, 2026 |
| KEYNOTE-B49 | 1 | #9 of 23 | Oct 24, 2026 |
| HERIZON-GEA-01 | 1 | #10 of 34 | Oct 23, 2026 |
| HORIZON-Breast06 | 1 | #4 of 15 | Oct 23, 2026 |
| PANKU-Breast01 | 1 | #11 of 23 | Oct 23, 2026 |
| OptiTROP-Lung05 | 1 | #18 of 19 | Oct 2, 2026 |
| FLAURA2 | 1 | #23 of 25 | Sep 28, 2026 |
| KEYNOTE-671 | 1 | #8 of 13 | Aug 21, 2026 |
| ASCENT03 | 1 | #7 of 19 | Jun 2, 2026 |
| PANKUBREAST02 | 1 | #2 of 3 | Jun 2, 2026 |
| ASCENT-04 | 1 | #12 of 24 | Jun 2, 2026 |
| POTOMAC | 1 | #13 of 17 | Jun 1, 2026 |
| RASolute 302 | 1 | #26 of 73 | May 31, 2026 |
| PROTEUS | 1 | #44 of 56 | May 31, 2026 |
| TALAPRO-3 | 1 | #20 of 39 | May 30, 2026 |
| OPTIMA (UK) | 1 | #18 of 24 | May 30, 2026 |
| CAPITELLO291 | 1 | #4 of 8 | May 7, 2026 |
| DESTINY-Breast11 | 1 | #6 of 11 | May 6, 2026 |
| VERITAC-2 (vepdegestrant) | 1 | #10 of 18 | May 2, 2026 |
| VERITAC-2 | 1 | #5 of 10 | May 2, 2026 |
Aya Mohamed | MSc, MD π on NATALEE
@OncoAlert @myESMO SOFT/TEXT, monarchE, NATALEE, and pregnancy after breast cancer data highlight the need to individualize treatment while preserving long-term quality of life.
Honored to be part of this discussion with OncoDaily and esteemed colleagues on the 6-year NATALEE data and its implications for breast cancer care. #ESMO26 #BreastCancer @OncoAlert #ESMOAmbassadors #ESMOcommunity @myESMO https://t.co/1a44Y2BqdD
NATALEE: 6-Year Update at #ESMO26 Adjuvant ribociclib + NSAI continues to improve iDFS in HR+/HER2β early breast cancer, with updated data showing an OS benefit (HR 0.81; 95% CI, 0.66β0.99) and improved #BreastCancer βspecific survival. @OncoAlert #bcsm @myESMO https://t.co/MUiDWRxCjG
Aya Mohamed | MSc, MD π on DESTINYBreast-09
DESTINY-Breast09: #ESMO26 T-DXd + pertuzumab showed encouraging systemic and intracranial activity in 1L HER2+ mBC with baseline brain metastases, with CNS-PFS HR 0.26 vs THP. @OncoAlert #BreastCancer #bcsm #ESMOAmbassadors #ESMOcommunity @myESMO https://t.co/FO2eHAPYUZ
DESTINY-Breast09 T-DXd + Pertuzumab defines a new depth-driven paradigm in 1L HER2+ metastatic breast cancer: >50% achieve CR/Deep PR (β₯80% tumor reduction) with progressively deepening responses over ~9 β 24 months. @OncoAlert #ASCO26 @BreastCancer #bcsm @ASCO https://t.co/iBpBSRvMX3
Redefining 1L HER2+ Metastatic #BreastCancer: From CLEOPATRA to ADC-Driven Precision Strategies 𧬠Emerging evidence from DESTINY-Breast09, HER2CLIMB-05, and PATINA highlights a major evolution toward biologically tailored frontline therapy integrating: @OncoAlert #ESMOBreast26 https://t.co/j8jG0xAuNJ
Aya Mohamed | MSc, MD π on DeLLphi-304
DeLLphi-304: π« Tarlatamab sustained its OS benefit at 23-month follow-up, improving median OS to 13.6 vs 8.4 months (HR 0.62) @OncoAlert #ESMO26 @ESMO_Open #ESMOAmbassadors #LungCancer #ESMOcommunity @myESMO https://t.co/tqxtg7Mg1p
DeLLphi-304: π« Tarlatamab Redefines CNS Control in Relapsed SCLC, Cutting Intracranial Progression Risk by 60% @ASCO @OncoAlert #Lcsm #ASCO26 https://t.co/PtC6MxGeRR
Aya Mohamed | MSc, MD π on OptiTROP-Lung06
OptiTROP-Lung06:π« Sac-TMT + pembrolizumab improved median PFS in PD-L1βnegative advanced nonsquamous NSCLC (15.0 vs 5.7 months; HR 0.49), with fewer grade 3 or higher adverse events. OS remains immature; follow-up is key. @OncoAlert #ESMO26 #LungCancer #ESMOcommunity @myESMO https://t.co/nIAg7uYbdI
OptiTROP-Lung06 π« Sac-TMT + pembrolizumab: A substantial PFS benefit in 1L PD-L1-negative advanced NSCLC, with OS data still immature. @OncoAlert #ESMO26 #LungCancer #Lcsm #ESMOAmbassadors #ESMOcommunity @myESMO https://t.co/XTv3FAFHOZ
Aya Mohamed | MSc, MD π on TROPION-Breast02
TROPION-Breast02 #ESMO26 In 1L mTNBC with brain metastases, Dato-DXd showed promising intracranial and systemic activity vs chemotherapy: β’ CNS PFS: 9.5 vs 2.6 months (HR 0.27) @OncoAlert #BreastCancer #Bcsm https://t.co/IfL8AktwcJ
TROPION-Breast02: Dato-DXd redefines 1L mTNBC beyond efficacy alone. A near 3-fold prolongation in QoL preservation vs chemotherapy (TTD 23.5 vs 8.3 mo; HR 0.64) signals a paradigm shift toward "quality survival" #ESMOBreast26 @OncoAlert #mTNBC #ADCs #bcsm https://t.co/ayxHw4qSDi
Aya Mohamed | MSc, MD π on postMONARCH
postMONARCH: Abemaciclib After CDK4/6 Inhibitor Progression β PFS Benefit Without a Statistically Significant OS Improvement @OncoAlert #BreastCancer #bcsm #ESMO26 https://t.co/qwKzc5cVZt
postMONARCH: CDK4/6 Inhibition Beyond Progression β Modest PFS Benefit, No Significant OS Benefit @OncoAlert #ESMO26 #BreastCancer https://t.co/9tp2n36twG
Aya Mohamed | MSc, MD π on DESTINYBreast-05
DESTINY-Breast05: PROs at #ESMO26 HRQoL was largely maintained with both T-DXd and T-DM1 in high-risk HER2+ early breast cancer with residual invasive disease. @OncoAlert #BCSM #BreastCancer https://t.co/3rroj3ppmI
DESTINY-Breast05 (Phase III) Practice changing data in HER2+ early breast cancer with residual disease post-NAT. T-DXd vs T-DM1 sets a new therapeutic benchmark in the adjuvant setting. π @OncoAlert #ASCO26 #BreastCancer #bcsm https://t.co/aYZv0ZOAE2
Aya Mohamed | MSc, MD π on HER2CLIMB-05
FDA approved tucatinib + trastuzumab + pertuzumab as maintenance therapy for HER2-positive unresectable locally advanced or metastatic #BreastCancer after THP induction. HER2CLIMB-05: PFS 24.9 vs 16.3 months; HR 0.64, P<0.0001. https://t.co/yMrKjog94D @OncoAlert #BCSM https://t.co/Ook2em9o1a
Redefining 1L HER2+ Metastatic #BreastCancer: From CLEOPATRA to ADC-Driven Precision Strategies 𧬠Emerging evidence from DESTINY-Breast09, HER2CLIMB-05, and PATINA highlights a major evolution toward biologically tailored frontline therapy integrating: @OncoAlert #ESMOBreast26 https://t.co/j8jG0xAuNJ
Aya Mohamed | MSc, MD πβs Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
NSABP B-42 (15-year data): #ESMO26 Extended letrozole reduces distant recurrence, but without a significant OS benefit. πΉ Node-positive: 4.4% absolute benefit πΉ Node-negative: 1.6% (not statistically significant) @OncoAlert #BreastCancer #bcsm https://t.co/BRlrSNdzPp
APEX-Breast01: #ESMO26 TQB2102 Delivers a Substantial PFS Benefit in HER2-Low Metastatic Breast Cancer, With OS and Long-Term Safety Still to Mature @OncoAlert #BreastCancer #Bcsm https://t.co/B5z8hNKLPb
Young women with early #BreastCancer: treatment decisions must balance recurrence risk, endocrine therapy intensification, germline BRCA status, and fertility goals. #ESMO26 @OncoAlert #bcsm #ESMOAmbassadors #ESMOcommunity https://t.co/bAAxkbpKWo
PREcoopERA Trial: Oral SERD Activity in Premenopausal HR+ Early #BreastCancer, Promise Without Replacement Yet 𧬠Giredestrant with or without ovarian suppression shows robust Ki67 reduction in premenopausal HR+ early breast cancer, β¬οΈβ¬οΈ @OncoAlert #ESMOBreast26 #bcsm https://t.co/cRu3ey19eh
PACE-LUNG #ESMO26 ctDNA-guided treatment intensification in EGFR-mutant NSCLC: Early molecular response as a guide to adaptive therapy π« #LungCancer @OncoAlert #LCSM https://t.co/VPeBO6ig5C